CorMedix price to free cash flow CRMD
Market value divided by free cash flow over the last twelve months, since 2025.
- Today, Nov 2, 2026
- 1.7×
- Peer median
- 11.7×
CorMedix's price to free cash flow is 1.7× as of Nov 2, 2026.
The median for 10 large drugmakers of a similar size is 11.7×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.7× | 1.7× | 12.9× |
| 2025 | 13.3× | 10.2× | 36.4× |
Against its peers
Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| CRMDCorMedix | 1.7× |
| ARVNArvinas | n/m |
| PBYIPuma Biotechnology | 12.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 18.4× |
| COLLCollegium Pharmaceutical | 2.3× |
| ABUSArbutus Biopharma | n/m |
| NATRNatures Sunshine Products | 11.7× |
| AMPHAmphastar Pharmaceuticals | 7.5× |
| OMEROmeros | n/m |
| ANABAnaptysbio | n/m |
| Peer median | 11.7× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on CorMedix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.